Antithrombotic therapy in valvular heart disease.
Whether antithrombotic therapy in elderly patients differs from that in younger populations depends on whether the risk for such bleeding differs in the elderly. Regarding long-term therapy with warfarin derivatives, evidence shows that there is a difference. The anticoagulation response to warfarin is exaggerated with advancing age. This article discusses antithrombotic therapies for valvular heart disease, including bioprosthetic and mechanical prosthetic heart valves, aspirin and dipyridamole in combination with oral anticoagulant therapy, antiplatelet agents alone or in combination with very low dose warfarin, tilting disk valves, valve position, first-generation valves compared with modern valves, interruption of anticoagulant therapy, and miscellaneous indications for antithrombotic therapy.
Stein
P D
PD
St. Joseph Mercy-Oakland Hospital, Pontiac, Michigan, USA. steinp@trinity-health.org
D000368:Aged; D000369:Aged, 80 and over; D001705:Bioprosthesis; D002986:Clinical Trials as Topic; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006349:Heart Valve Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D006350:Heart Valve Prosthesis; D006801:Humans; D008297:Male; D011322:Primary Prevention / Q000379:methods; D013923:Thromboembolism / Q000188:drug therapy* / Q000517:prevention & control*; D016896:Treatment Outcome
D005343:Fibrinolytic Agents